Quarterly ResultJul 30, 2026, 04:15 PM
Stryker Q2 Net Sales $6.6B, Adjusted EPS $3.69
AI Summary
Stryker reported strong second quarter 2026 operating results, with reported net sales increasing 9.4% to $6.6 billion and organic net sales growing 9.0%. Adjusted diluted EPS rose 17.9% to $3.69. The company's CEO, Kevin A. Lobo, highlighted significant progress in recovery from a cyber incident and expressed confidence in future growth. Stryker also narrowed its full-year 2026 guidance, now expecting organic net sales growth of 8.3% to 9.3% and adjusted net earnings per diluted share in the range of $14.95 to $15.10.
Key Highlights
- Reported net sales increased 9.4% to $6.6 billion in Q2 2026.
- Organic net sales grew 9.0% in the second quarter.
- Adjusted operating income margin increased 170 bps to 27.4%.
- Reported diluted EPS rose 44.1% to $3.30; Adjusted diluted EPS increased 17.9% to $3.69.
- MedSurg and Neurotechnology net sales increased 9.7% to $3.6 billion.
- Orthopaedics net sales increased 9.1% to $3.0 billion.
- Full-year 2026 organic net sales growth guidance narrowed to 8.3%-9.3%.
- Full-year 2026 adjusted EPS guidance narrowed to $14.95-$15.10.
Price Impact
More from SYK